ICUI Key Statistics, Chart & Performance
The current stock price of ICUI is 158.54 USD. In the past month the price increased by 6.88%. In the past year, price decreased by -7.99%.
ICUI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ICUI. When comparing the yearly performance of all stocks, ICUI turns out to be only a medium performer in the overall market: it outperformed 69.82% of all stocks.
ICUI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ICUI. ICUI has only an average score on both its financial health and profitability.
ICUI Financial Highlights
Over the last trailing twelve months ICUI reported a non-GAAP Earnings per Share(EPS) of 7.96. The EPS increased by 40.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.18% | ||
| ROE | -0.35% | ||
| Debt/Equity | 0.62 |
ICUI Forecast & Estimates
12 analysts have analysed ICUI and the average price target is 185.03 USD. This implies a price increase of 16.71% is expected in the next year compared to the current price of 158.54.
For the next year, analysts expect an EPS growth of 23.92% and a revenue growth -4.6% for ICUI
ICUI Ownership
About ICUI
Company Profile
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 15,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
Company Info
ICU MEDICAL INC
951 Calle Amanecer
San Clemente CALIFORNIA 92763 US
CEO: Vivek Jain
Employees: 15000
Phone: 19493662183
ICU MEDICAL INC / ICUI FAQ
What does ICU MEDICAL INC do?
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 15,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
Can you provide the latest stock price for ICU MEDICAL INC?
The current stock price of ICUI is 158.54 USD. The price increased by 2.2% in the last trading session.
Does ICUI stock pay dividends?
ICUI does not pay a dividend.
How is the ChartMill rating for ICU MEDICAL INC?
ICUI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about ICU MEDICAL INC (ICUI) stock?
12 analysts have analysed ICUI and the average price target is 185.03 USD. This implies a price increase of 16.71% is expected in the next year compared to the current price of 158.54.
Is ICU MEDICAL INC (ICUI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ICUI.
What is the expected growth for ICUI stock?
The Revenue of ICU MEDICAL INC (ICUI) is expected to decline by -4.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.